Category Archives: Biotechnology

PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune today announced its financial results for the full year ended December 31, 2019 and provided a business update.

Fourth Quarter 2019 and Recent Business Highlights

We have made significant progress over the last year as we transitioned to a public company, strengthened our partnerships with leaders in immuno-oncology, such as Merck and National Cancer Institute and reported encouraging human data from our lead program, PDS0101, commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotechnology. As we forge ahead in 2020, we look forward to leveraging the highly encouraging Phase I human clinical outcome data, which demonstrated complete lesion regression in 60% of evaluable patients with cervical intraepithelial neoplasia (CIN) and human papillomavirus (HPV) within 1-3 months of treatment. These results support our combination approach in our upcoming clinical trials and provide evidence that PDS0101 could be essential in expanding the clinical efficacy of checkpoint inhibitors and improving clinical outcomes for patients.

With a strengthened balance sheet, we look forward to initiating three studies, including; a Phase 2 combination study to evaluate PDS0101 in combination with KEYTRUDA in the first line treatment of metastatic head and neck cancer, a Phase 2 study to evaluate PDS0101 in combination with two promising immune-modulating agents in advanced HPV-associated cancers with the NCI and a Phase 2a study to evaluate the combination of PDS0101 and chemoradiation in patients with locally advanced cervical cancer. We remain committed to developing our novel Versamune platform in collaboration with our partners and would like to thank our shareholders for their continued support, concluded Dr. Bedu-Addo.

Full Year 2019 Financial Review

For the year ended December 31, 2019, the net loss was approximately $6.9 million, or $1.44 per basic and diluted share. This compares to a net loss of approximately $3.8 million, or $1.15 per basic and diluted share for the year ended December 31, 2018.

For the year ended December 31, 2019, research and development expenses increased approximately 634% to approximately $6.1 million compared to approximately $0.8 million in the prior year. The increase is primarily attributable to an increase in external expenses for clinical studies, internal R&D personnel costs, non-cash stock-based compensation and departmental costs.

For the year ended December 31, 2019, general and administrative expenses increased approximately 294% to approximately $11.0 million compared to approximately $2.8 million in the prior year. The increase was due to increases in personnel costs, non-cash stock-based compensation, facilities costs, D&O insurance costs, legal fees, professional fees and other operating expenses.

For the year ended December 31, 2019, total operating expenses increased approximately 477% to approximately $21.0 million compared to approximately $3.6 million in the prior year.

As of December 31, 2019, the Companys cash balance was approximately $12.2 million. This amount does not include the approximately $11.9 million in net proceeds after deducting underwriting discounts and commissions, not including other offering expenses from PDS Biotechs underwritten public offering including the full exercise of the underwriters overallotment option, which closed in February.

About PDS Biotechnology

PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotech is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechs pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with the chemoradiotherapy, which is the standard of care.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; potential adverse reactions or changes to business relationships resulting from the resignation of the Companys Chief Financial Officer or the Companys ability to find a replacement Chief Financial Officer; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

(Financial Statements to Follow)

PDS BIOTECHNOLOGY CORPORATION and Subsidiaries

Consolidated Balance Sheets

PDS BIOTECHNOLOGY CORPORATION and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

See original here:
PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update - BioSpace

HIPRA, the multinational Animal Health company, which has its headquarters in Amer (Girona), has reached an agreement with the health authorities that will allow the principal hospitals in the province of Girona to make use of its new facilities (nearly 700 m2 of laboratories equipped with the latest PCR diagnostic technology), thus helping to streamline the management and production of results of tests for coronavirus SARS-CoV-2.

These are facilities that the company had just finished building at its headquarters as part of its business expansion plan and that it was about to open.

As an Animal Health company, for us it is a duty and an act of responsibility to make use of all the resources that we have in order to help preserve public health in such exceptional times, hence the need to collaborate by giving over our new diagnostic centres, the company announced.

The samples received will come from different hospitals in the region and will be processed in accordance with international protocols and the strictest biosecurity and biocontainment measures. Staff from the hospitals, and from various local biotechnology startups who are parties to this agreement, will move to HIPRAs facilities and will be responsible for the entire process of analysis, whilst the companys experts will provide support with their knowledge and experience in biotechnology.

HIPRA develops and sells vaccines for animals, and also provides a variety of services for the prevention and control of various animal diseases on livestock farms. It uses the latest PCR analysis technology for the diagnosis of these diseases.

This type of real-time diagnosis allows hundreds of samples to be analysed in a few hours, backed up by the automation of the process, so we are convinced that this will be of great help explained the company.

It is estimated that this collaboration will last for 2 or 3 weeks and will remain in force for as long as the health authorities need our help in the current health emergency, announced the company.

HIPRA is also producing components for the manufacture of medical ventilators by 3D printing which will also be supplied to hospitals in the region. This project is being co-ordinated through companies and institutions such as HP, LEITAT Managing Technologies and other public bodies.

The company has anticipated and introduced a whole series of measures to preserve the health of its employees and everyone around them. HIPRA is continuing to manufacture and distribute its medicinal products, which is essential both to ensure the supply of healthy food to the population and to maintain the health of our pets who share our homes.

We have a duty to keep up our normal levels of production as we make a vital contribution to the food supply chain and to the health of the population with products that are considered to be basic essentials

Read more from the original source:
HIPRA makes part of its biotechnology facilities and equipment available to the health authorities - The Poultry Site

Nearly every U.S. industry is struggling with the effects of the pandemic. Only one has a shot at stopping the virus itself.

Over the past decade, biotechnology firms and pharmaceutical companies have stockpiled an armament of scientists, laboratories, and capital in the billions of dollars. Those labs could end the current global nightmare of Covid-19.

Are they doing enough?

Now, after a slow start, there are nearly 60 programs under way to develop a Covid-19 treatment and more than 40 to develop a vaccine, by both commercial and noncommercial labs, according to an accounting by the Milken Institute.

Brian Abrahams, an analyst at RBC Capital Markets, thinks the biotech industry should be doing much more.

We havent seen the broader biotech community come together in a really cohesive way to try to tackle this problem, Abrahams said in an interview on Monday. There are hundreds of companies, tons of talent, and a lot greater understanding of biology and drug discovery than weve ever had.

In recent days, signs of an industrywide movement, like the one Abrahams called for, have begun to emerge, with a biotechnology industry group holding a virtual gathering to coordinate a response.

And generic-drug companies have now rushed to make available a medication that has shown early promise as a Covid-19 therapy.

If youre a mid- or large-cap company, I think its almost a societal duty to be making some effort to leverage whatever expertise you might have.

Its my personal belief that this is the mission of the pharmaceutical industry, says Sol Barer, chairman of the board of Teva Pharmaceutical Industries (ticker: TEVA) and a co-founder of the biotech firm Celgene, which was recently acquired by Bristol-Myers Squibb (BMY). We are here to discover, develop, and commercialize drugs, especially for serious, fatal diseases.

For drugmakers of all types, Covid-19 offers a chance to rehabilitate their image before an American public that has grown increasingly frustrated with high prices and ethical scandals like the opioid crisis and generic-drug price-fixing allegations.

The pharmaceutical industry does have an opportunity here to both help and also to accomplish a very important aspect of rebranding, says Dan Mendelson, founder of Avalere Health, a health-care consulting firm.

It remains unlikely that companies will make money off their Covid-19 programs, but burnishing the industrys image will bring its own value.

Even with no profit motive, says Abrahams, companies should be putting virtually everything aside to work on Covid-19 treatments. If youre a mid- or large-cap company, I think its almost a societal duty to be making some effort to leverage whatever expertise you might have, he says.

Among the Covid-19 research programs in progress are a number of attempts to use messenger RNA to make vaccines that train the body to defend against the virus. Biotech firm Moderna (MRNA) already has an mRNA vaccine in the clinic. BioNTech (BNTX) is working with Pfizer (PFE) and a Chinese company on their own version, Translate Bio (TBIO) is developing one with Sanofi (SNY), and so is the private firm CureVac

Therapeutics under investigation include repurposed antivirals such as Gilead Sciences (GILD) remdesivir and AbbVies (ABBV) Kaletra. Other companies are working on antibody therapies, including Regeneron Pharmaceuticals (REGN) and Vir Biotechnology (VIR), which is teaming up with Biogen (BIIB).

According to Jeremy Levin, CEO of Ovid Therapeutics (OVID) and chairman of the board of the industry group Biotechnology Innovation Organization, or BIO, some 45 biotechs have Covid-19 programs.

Still, that represents only a portion of biotech. Much of the biopharmaceutical industry, like many other industries, has been shut down by the pandemic.

Laboratories are operating with skeleton crews. Companies like Eli Lilly (LLY) and Bristol-Myers have delayed the starts of new drug clinical trials, and armies of salespeople have been effectively grounded. That leaves a lot of capital sitting there while people are dying.

The reality is, from a commercial standpoint, companies with marketed products are not really going to be able to spend the same amount of money on sales costs now, with the country in virtual lockdown, nor will they be able to continue most of their clinical trials until this passes, Abrahams says. Theres a natural bandwidth expansion.

BIOs Levin says that there is a limit to how many biotech companies can tackle Covid-19.

Its very difficult for companies to switch on a dime, he says. If youre a cancer company, its very difficult to switch to being an antiviral company. Half of biotechnology, Levin notes, is focused on cancer.

Still, Levin says, in recent days, the sector has been working to coordinate its Covid-19 response. On Tuesday and Wednesday, BIO organized a virtual summit meant in part to connect the companies working on Covid-19 with government agencies.

From my perspective, theres no one solution, he says. Its a comprehensive Marshall Plan, which goes across all of these companies.

Levin says that one way to bring more companies into the effort is by encouraging collaborations. He highlights an effort by Vir, which focuses on infectious disease, and Alnylam Pharmaceuticals (ALNY), which specializes in a modality called RNA interference, on an RNAi approach to curing Covid-19.

Outside of biotechnology, the pharmaceutical giants have announced their own efforts.

And in a wave this week, generic drugmakers announced plans to ramp up productions of hydroxychloroquine, an antimalarial drug that has shown promise as a Covid-19 treatment. Teva alone donated six million doses of the drug.

The way we can help is, if there are drugs now that are available and generic, we can help supply them in significant quantities, Tevas Barer says. If we make it, we will supply it, we will supply it quickly.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

View post:
Biotech and Big Pharma Join Fight Against Covid-19. Why They Need to Do More, - Barron's

While biotech stocks are often too risky for many investors, with the coronavirus raging and the race for a vaccine in play, taking a look at some ETFs that contain biotech stocks that are making strides might not be such a bad idea.

With the COVID-19 pandemic raging, biotechs that are consistently profitable and that offer drugs that patients absolutely must have could be seen as relatively safe compared to many other stocks on the market. For investors looking to stay in the market and diversify portfolios, here are two biotech ETFs that could be worth diversifying into during the coronavirus crisis.

With biotech companies like Gilead Sciences, which has been in the news a lot recently for the antiviral drug remdesivir, which appears to be the most promising treatment for COVID-19, IBB is a place for biotech investors to consider. Gilead is conducting late-stage studies of the drug and could report initial results as early as April. Gilead also has adividend yield currently stands at nearly 4%. The company has even augmented its dividend by 58% over the last five years.

IBB seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

While the iShares Genomics Immunology and Healthcare ETF has no directly related coronavirus drug-making companies in its holdings, it does contain stocks like Exelixis, which makes drugs that are used to treat kidney, liver, and medullary thyroid cancer, which will continue to be important going forward. The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

For more market trends, visitETF Trends.

See the rest here:
2 Biotechnology ETFs That Could Be Good For Diversification - ETF Trends

For biotech companies, responding to a sudden public health crisis, such as the coronavirus, can be a risky business. It can take more than a year to develop a vaccine or treatment. By then, the threat could be gone, leaving little or no demand for medicine.

The current coronavirus pandemic looks different.

The race to beat the pathogen continues, with many biotechnologies now anticipating a large market for coronavirus therapy in 2021 or thereafter. But the starting gun did not fire as soon as the virus started spreading late last year.

There have been many companies that feel bitten once, shy twice, said Jose Travejo, CEO of SmartPharm Therapeutics in Kendall Square.

Companies were shy because drug makers were bitten in the past when they rushed to tackle an epidemic, only to see the danger go away and their efforts go to waste. This happened during a previous coronavirus scare, the 2003 SARS epidemic, which ended before any vaccine maker made money.

There was also Ebola. Then many people forget about swine flu H1N1, Travejo said. So, I think very big pharmacists are hesitant to dive completely into coronavirus.

The opinion of the industry has changed in recent weeks. At LabCentral, the shared workspace where Travejo gene therapy is launched, more than a dozen companies have turned their attention to coronavirus, including SmartPharm.

And this is just one lab in Cambridge.

The number of companies pursuing coronavirus drugs is steadily increasing, according to Yasmen Rahimi, co-director of biotechnology research at Roth Capital Partners, an investment banking firm in Newport Beach, California.

I follow COVID-19 daily, she said. Almost every day we get 10 or 12 companies coming.

Rahimi said the most notable may be Modern, another Cambridge biotech. It is the first company to begin testing a potential coronavirus vaccine for people in the United States.

Modern did not respond to an interview request. But in a public document this week, the company said it was probably not commercially available for the vaccine for at least 12-18 months.

Modern does not think that the virus will enter until then. Instead, its increasing production capacity to produce millions of doses per month.

That may not be enough, according to Dr. Lee Wetzler, an infectious disease specialist at Boston Medical Center.

Just like the flu vaccine, youre not just talking about millions of doses, said Wetzler, who is also a professor at Boston University School of Medicine. Tens tens of millions of doses and more.

Then again, Wetzler added, its hard to predict what this unknown virus will look like in a year. The pandemic may be under control, which would be good for the world, but it may not be as good for companies like Moderna and others who invest in medicines to stop it.

There is a cautionary tale in the once hot biotech Vical that received federal money to chase anthrax, SARS and Ebola vaccines. Fear and funding always fade before Vical manages to cross the finish line, said John Carroll, editor of Endpoints News, a biotechnology publication.

What Vical did was just a flame, he said. They couldnt come up with a vaccine, and after multiple setbacks, they just couldnt do it anymore.

The risk of failure is well understood by James Siestra, CEO of Totient, one of the startup companies at LabCentral that have switched to coronavirus. But he claims that working with the coronavirus will not be useless, even if the disease goes ahead before Totient puts the drug on the market.

As a business case for us, this is great evidence of the strength of our platform, he said.

Sietstra said the same method that Totient would use to attack the coronavirus could be used against other diseases including the companys original goal cancer.

Originally posted here:
Developing vaccines is a risky business. Biotechnology is fighting the coronavirus anyway - Mash Viral

New Jersey, United States:The Nanoparticles in Biotechnology and Pharmaceuticals Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Nanoparticles in Biotechnology and Pharmaceuticals market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Nanoparticles in Biotechnology and Pharmaceuticals Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Nanoparticles in Biotechnology and Pharmaceuticals market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Nanoparticles in Biotechnology and Pharmaceuticals market.

The main players featured in the Nanoparticles in Biotechnology and Pharmaceuticals market report are:

Leading players of the Nanoparticles in Biotechnology and Pharmaceuticals market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Nanoparticles in Biotechnology and Pharmaceuticals market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Nanoparticles in Biotechnology and Pharmaceuticals market. It also provides useful recommendations for new as well as established players of the Nanoparticles in Biotechnology and Pharmaceuticals market.

Nanoparticles in Biotechnology and Pharmaceuticals Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Nanoparticles in Biotechnology and Pharmaceuticals market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Nanoparticles in Biotechnology and Pharmaceuticals.

Analysts who have authored the report have segmented the market for Nanoparticles in Biotechnology and Pharmaceuticals by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Nanoparticles in Biotechnology and Pharmaceuticals market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=SGN&utm_medium=003

Highlights of TOC:

Overview: In addition to an overview of the Nanoparticles in Biotechnology and Pharmaceuticals market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Nanoparticles in Biotechnology and Pharmaceuticals.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Nanoparticles in Biotechnology and Pharmaceuticals.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Nanoparticles in Biotechnology and Pharmaceuticals market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Nanoparticles in Biotechnology and Pharmaceuticals market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=SGN&utm_medium=003

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Our Trending Reports

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Excerpt from:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and...

New Jersey, United States:The Agricultural Biotechnology Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Agricultural Biotechnology market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Agricultural Biotechnology Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Agricultural Biotechnology market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Agricultural Biotechnology market.

Global Agricultural Biotechnology Market was valued at USD 35.6 Billion in 2018 and is projected to reach USD 74.92 Billion by 2026, growing at a CAGR of 9.70% from 2019 to 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=35624&utm_source=SGN&utm_medium=009

The main players featured in the Agricultural Biotechnology market report are:

Leading players of the Agricultural Biotechnology market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Agricultural Biotechnology market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Agricultural Biotechnology market. It also provides useful recommendations for new as well as established players of the Agricultural Biotechnology market.

Agricultural Biotechnology Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Agricultural Biotechnology market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Agricultural Biotechnology.

Analysts who have authored the report have segmented the market for Agricultural Biotechnology by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Agricultural Biotechnology market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=SGN&utm_medium=009

Highlights of TOC:

Overview: In addition to an overview of the Agricultural Biotechnology market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Agricultural Biotechnology.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Agricultural Biotechnology.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Agricultural Biotechnology market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Agricultural Biotechnology market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=SGN&utm_medium=009

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Agricultural Biotechnology Market Size, Agricultural Biotechnology Market Trends, Agricultural Biotechnology Market Forecast, Agricultural Biotechnology Market Growth, Agricultural Biotechnology Market Analysis

Our Trending Reports

Threat Intelligence Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Here is the original post:
Agricultural Biotechnology Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 -...

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $30.85 to be very precise. The Stock rose vividly during the last session to $37.4 after opening rate of $37 while the lowest price it went was recorded $30.22 before closing at $32.75.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.87% during the 52-week period from high price, and 164.80% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 562686 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 160.44%, having the revenues showcasing 166.91% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.13B, as it employees total of 217 workers.

During the last month, 2 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 20.80, with a change in the price was noted +16.66. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +115.45% for the period of last 100 days, recording 527,790 in trading volumes.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 29.02%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 7.73%. In the last 20 days, the companys Stochastic %K was 19.17% and its Stochastic %D was recorded 29.17%.

Lets take a glance in the erstwhile performances of Vir Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 160.44%. The shares increased approximately by 1.54% in the 7-day charts and went down by -34.84% in the period of the last 30 days. Common stock shares were driven by 166.91% during last recorded quarter.

Read more here:
Gear up for the change! Vir Biotechnology, Inc. (VIR) has hit the volume of 562686 - The InvestChronicle

The 85 rating InvestorsObserver gives to Aytu Bioscience Inc (AYTU) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, AYTUs 85 overall rating means the stock scores better than 85 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aytu Bioscience Inc (AYTU) stock is down -16.08% while the S&P 500 has risen 3.65% as of 2:13 PM on Wednesday, Mar 25. AYTU has fallen -$0.32 from the previous closing price of $1.99 on volume of 21,555,025 shares. Over the past year the S&P 500 has fallen -10.00% while AYTU has risen 3.73%. AYTU lost -$1.88 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more here:
Is Aytu Bioscience Inc (AYTU) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Global Agriculture Biotechnology Market 2019, this report is prepared by in-depth analysis of historical data. The report forecasts the market size by the end of 2026 at an impressive CAGR provided by Reports and Reports. The report offers detailed outline of Agriculture Biotechnology Market and vital market trends. The prime agenda of this report is to provide a detailed analysis of the global, regional and country-level market size, market growth, market status, forecast, sales analysis, value chain optimization, trade regulations, recent developments, opportunities analysis, and importance of the global and national market players, competitive environment, expansion, acquisition, partnerships and technological innovations. The prime market segments considered to prepare this report are key players, regional segments, type and application.

Get Free Sample Copy of Agriculture Biotechnology Market: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/#RequestSample

The Agriculture Biotechnology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The major players covered in Agriculture Biotechnology Market are: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto.

Agriculture Biotechnology Industry 2020 Global Market Research report presents an in-depth analysis of the Agriculture Biotechnology market size, growth, share, segments, manufacturers, and technologies, key trends, market drivers, challenges, standardization, deployment models, opportunities, future roadmap and 2026 forecast. The report additionally presents forecasts for Agriculture Biotechnology market revenue, consumption, production, and growth drivers of the market.

Get Special Discount on this report: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/#AskForDiscount

Regions and Countries Level Analysis:

The important regions, considered to prepare this report are North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The region wise data analyses the trend, market size of each regions Agriculture Biotechnology Market.

Table of Content (TOC)

Chapter 1: Product definition, type and application, Global market overview;

Chapter 2: Global Market competition by company;

Chapter 3: Global sales revenue, volume and price by type;

Chapter 4: Global sales revenue, volume and price by application;

Chapter 5: United States export and import;

Chapter 6: Company information, business overview, sales data and product specifications;

Chapter 7: Industry chain and raw materials;

Chapter 8: SWOT and Porters Five Forces;

Chapter 9: Conclusion.

Continue

List of Tables and Figures

Get Detail information of this report: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Agriculture Biotechnology Market forecast of till 2026. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

Read more:
Global Agriculture Biotechnology Market Expected to Witness the Highest Growth with ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury...